Composite Disease Activity and Responder Indices for Psoriatic Arthritis: A Report from the GRAPPA 2013 Meeting on Development of Cutoffs for Both Disease Activity States and Response

REFERENCES

1. 1.↵
   1. Felson DT,
   2. Anderson JJ,
   3. Boers M,
   4. Bombardier C,
   5. Furst D,
   6. Goldsmith C,
   7. et al.

   American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. van Gestel AM,
   2. Prevoo ML,
   3. van ‘t Hof MA,
   4. van Rijswijk MH,
   5. van de Putte LB,
   6. van Riel PL

   . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34–40.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Fransen J,
   2. Antoni C,
   3. Mease PJ,
   4. Uter W,
   5. Kavanaugh A,
   6. Kalden JR,
   7. et al.

   Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373–8.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Coates LC,
   2. FitzGerald O,
   3. Gladman DD,
   4. McHugh N,
   5. Mease P,
   6. Strand V,
   7. et al.

   Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum 2013;65:1504–9.

   OpenUrlPubMed
5. 5.↵
   1. Clegg DO,
   2. Reda DJ,
   3. Mejias E,
   4. Cannon GW,
   5. Weisman MH,
   6. Taylor T,
   7. et al.

   Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013–20.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Helliwell PS,
   2. FitzGerald O,
   3. Fransen J,
   4. Gladman DD,
   5. Kreuger GG,
   6. Callis-Duffin K,
   7. et al.

   The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Mumtaz A,
   2. Gallagher P,
   3. Kirby B,
   4. Waxman R,
   5. Coates LC,
   6. Veale JD,
   7. et al.

   Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272–7.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Nell-Duxneuner VP,
   2. Stamm TA,
   3. Machold KP,
   4. Pflugbeil S,
   5. Aletaha D,
   6. Smolen JS

   . Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546–9.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Helliwell PS,
   2. Kavanaugh A

   . Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res 2013 (E-pub ahead of print).
10. 10.↵
    1. Fransen J,
    2. van Riel PL

    . The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23 Suppl 39:S93–9.

    OpenUrlPubMed